Long Shortz with Orthocell: Nerve repair product ready for US domination on $17M raise

Orthocell’s CEO and managing director Paul Anderson joins Sarah Hughan on Stockhead TV to talk about the company’s institutional placement for its regenerative medicine treatments.

OCC (1)

Stockhead’s Sarah Hughan sits down with Orthocell's (ASX:OCC) CEO and managing director Paul Anderson to get the short end of the long story on the company’s latest news.

The company raised $17M via an institutional placement to fully fund the launch of Remplir into the key US market via the Food and Drug Administration.

Remplir is a collagen wrap used in the repair of peripheral nerve injuries, providing compression-free protection to the nerve, creating an ideal microenvironment to aid nerve healing.

Tune in to hear Orthocell's Paul Anderson who's utilising the technology, who supported the placement, and more.

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Orthocell: Nerve repair product ready for US domination on $17M raise